News

An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration

Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one

Quotient Technology (NYSE: QUOT) shareholders had a great to start to the trading week. The digital promotions and media tech specialist's stock jumped 16% in early trading, compared to a nearly 1%

AT&T (NYSE: T) and Amazon (NASDAQ: AMZN) are both often considered stable long-term investments. AT&T is one of the largest telecom companies in the United States, and it has paid continuous

Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have

Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase

Fool.com contributor and finance professor Parkev Tatevosian compares AT&T (NYSE: T) and Deere (NYSE: DE) to determine which is the better dividend stock to buy.

*Stock prices used were the

On June 11, the gene sequencing giant Illumina (NASDAQ: ILMN) announced that its CEO, Francis deSouza, resigned after a tenure of roughly 10 years and that the company would start looking for a

Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race. The stock climbed more than 2,700% in 2020.

But as the biotech company fell behind in the race, so did its shares. Novavax

Nano-X Imaging (NASDAQ: NNOX), DermTech (NASDAQ: DMTK), and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk.

Share

Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to

Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive

While 2022 was disastrous for much of the market, 2023 is shaping up to be much better, with the S&P 500 already up nearly 15% so far this year. Long-term investors understand that these ups and

Shares of health insurance benefits managers dropped last Wednesday after the largest member of their industry, UnitedHealth Group (NYSE: UNH), issued a minor warning. Speaking at an investor

Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug

Nvidia's (NASDAQ: NVDA) explosive growth in its data center segment recently overtook gaming as the company's largest source of revenue. But gaming is still a large business, generating a third of

For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed

Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a

An up-and-coming stock with lots of potential is Viking Therapeutics (NASDAQ: VKTX). Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a

Buy on the dip. Most investors have heard the old saying. However, it's only good advice when a stock is likely to rebound strongly.

Three Motley Fool contributors think they've identified stocks

Axsome Therapeutics (NASDAQ: AXSM) stock jumped more than 10% on June 14 after the company made its latest investor presentation public. The market was reacting to new estimates that suggest peak